Nalmefene for Reducing Alcohol Consumption in People with Alcohol Dependence (TA325)

Technology Appraisal Guidance No. 325

Source: National Institute for Health and Care Excellence

1. Guidance

1.1 Nalmefene is recommended within its marketing authorisation, as an option for reducing alcohol consumption, for people with alcohol dependence:

  • who have a high drinking risk level (defined as alcohol consumption of more than 60 g per day for men and more than 40 g per day for women, according to the World Health Organization's drinking risk levels) without physical withdrawal symptoms and
  • who do not require immediate detoxification.

The marketing authorisation states that nalmefene should:

  • only be prescribed in conjunction with continuous psychosocial support focused on treatment adherence and reducing alcohol consumption and
  • be initiated only in patients who continue to have a high drinking risk level 2 weeks after initial assessment.

The guidance shown above constitutes Section 1 of the full document. A copy of the full document and a summary of the evidence is available on the Internet at

This guidance represents the view of the Institute which was arrived at after careful consideration of the available evidence. Health professionals are expected to fully take it into account when exercising their clinical judgement. This guidance does not, however, override the individual responsibility of health professionals to make appropriate decisions in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

© Copyright National Institute for Health and Care Excellence. All rights reserved. This material may be freely reproduced for educational and not for profit purposes within the NHS. No reproduction by or for commercial organisations is permitted without the express written permission of the Institute.

Enquiries concerning the guidance should be addressed to: National Institute for Health and Care Excellence, MidCity Place, 71 High Holborn, London WC1V 6NA. email:

Nalmefene for reducing alcohol consumption in people with alcohol dependence.

Issue Date: November 2014

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

More from MIMS

Drug shortages - live tracker

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

Live updates: Coronavirus (COVID-19) in the UK

Live updates: Coronavirus (COVID-19) in the UK

Use our timeline to follow the latest coronavirus developments...

Consider bisphosphonates to combat osteoporosis risk in asthma patients taking steroids, say researchers
Medicines shortages increase as prescribing costs rise £158 million

Medicines shortages increase as prescribing costs rise £158 million

Increasing medicines shortages have added more than...